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Simple Summary: Breast cancer is the most prevalent type of cancer worldwide. By late 2020, there were
7.8 million women alive who had been diagnosed with breast cancer during the previous 5 years. HER2
overexpression in breast cancer is associated with poor prognosis. Existing HER2-targeting therapies
significantly improved patient outcomes; still, designing these personalized treatments relies on accurate
and comprehensive assessment of HER2 alterations. Frequent HER2 status determination during disease
monitoring can be performed using circulating tumour cells (CTCs). Using a novel microfluidic device,
we isolated and enumerated CTCs from metastatic breast cancer patients and assessed their HER2
expression in a comparative study with the current gold standard technology. CTCs isolated with our
microfluidic technology showed to be a valuable biomarker, and their phenotypical analysis hinted utility
to discriminate patient populations, although further validation is needed.
Abstract: HER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour
biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour
and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot
of the tumour burden. Liquid biopsy offers the unique opportunity for low invasive sampling in cancer
patients and holds the potential to provide valuable information for the clinical management of cancer
patients. This study assesses the performance of the RUBYchip™, a microfluidic system for CTC capture
based on cell size and deformability, and compares it with the only FDA-approved technology for CTC
enumeration, CellSearch®. After optimising device performance, 30 whole blood samples from metastatic
breast cancer patients were processed with both technologies. The expression of HER2 was assessed in
isolated CTCs and compared to tissue biopsy. Results show that the RUBYchipTM was able to isolate CTCs
with higher efficiency than CellSearch®, up to 10 times more, averaging all samples. An accurate evaluation
of different CTC subpopulations, including HER2+ CTCs, was provided. Liquid biopsy through the use of
the RUBYchipTM in the clinic can overcome the limitations of histological testing and evaluate HER2 status
in patients in real-time, helping to tailor treatment during disease evolution.
Keywords: breast cancer; HER2; circulating tumour cells; liquid biopsy; microfluidics; overall survival
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1. Introduction
Breast cancer is the second most common cancer in the world and one of the leading
causes of cancer-related mortality in women, with main incidence between 35 and 75 years
old [1,2]. In most of cases, the disease appears sporadically; however, in about 5% of the
cases the disease is hereditary with a mutation in coding DNA, leading to a high risk of
developing cancer during life [1,3–5]. Clinical management and technological advance-
ments allow most primary and early-stage breast cancers to be treated, either by surgery
alone or surgery and complementary therapy, achieving an overall 5-year survival rate
of 90% [6]. Nevertheless, when cancer spreads and metastasis occurs, the 5-year survival
rate drops to 26% [7–9]. Research efforts to improve survival rates for metastatic breast
cancer (MBC) are currently focused on identifying the molecular heterogeneity of breast
cancer and in classifying patients into meaningful subgroups. This classification allows
to stratify patients according to prognosis and to define the best therapeutic approach for
each group [1].
Nowadays breast cancer can be classified into four molecular subtypes: luminal A,
luminal B, basal-like and human epithelial growth factor receptor 2 (HER2) overexpres-
sion [1,10,11]. Tumours in the luminal groups present hormonal receptors (oestrogen
receptor and/or progesterone, ER+ and/or PR+). Luminal A tumours have high expres-
sion levels of hormone-activated genes and low levels of proliferation, being classified as
low histological grade (1–2) and good outcome, also with no expression of HER2. On the
other hand, luminal B tumours have higher histological grade (2–3), higher proliferation
rates and overexpression of HER2 and, consequently, worse prognosis [10–13]. The other
subtypes, basal-like and HER2, are related to the lack of hormonal receptors (ER− and
PR−) [10] and associated with aggressiveness and complicated clinical behaviour [1,10].
Basal-like tumours, also known as triple-negative breast cancer, lack also expression of
HER2 receptors and represent 15–20% of the cancers, usually having unfavourable diagno-
sis and outcome, with high histological grade (3), high proliferative index and higher risk of
metastases [13–19]. HER2 tumours display an overexpression of the HER2 protein and asso-
ciated genes, and they show rapid growth, high histological grade (2–3) and poor behaviour
in the therapy [20,21]. HER2 is a member of the epidermal growth factor receptor (EGFR)
family of homologous transmembrane receptor tyrosine kinases (RTK) [22–25] present
in 20–30% of breast cancers, having an important role in the progression of the disease,
associated with an aggressive disease course and poor survival [22,23,26]. In recent years
the survival of HER2 patients has improved with the use of targeted anti-HER2 therapy,
achieving survival rates of 43% [27] (OS improved from 20.3 months to 48 months in [28]).
Breast cancer and its expression profile can be studied through tissue biopsy, which
aids in subtype classification and grading and is used to define individual therapeutic
strategies. If disease relapse happens, treatment decisions are normally still made based
on the tissue biopsy of the primary tumour, even when relapse occurs many years after
the first diagnosis. A new tissue biopsy is only performed if the tumour site is accessible,
when the patient does not respond to therapy. Monitoring of disease progression and eval-
uation of clinical response relies on biochemical analysis and radiological examination [29].
However, cancer is a heterogeneous and dynamic disease in constant clonal evolution [30],
meaning that the tumour characteristics may change over time and across different tumour
locations [2,30]. Hence, tissue biopsy often fails to represent intra-tumour and inter-tumour
heterogeneity, as it relies on a limited sample of tumour tissue.
Liquid biopsy is a minimally invasive and painless method that provides continu-
ous, reliable and real-time information on the tumour progression through the molecular
analysis of circulating biomarkers, overcoming the limitations of the clinical procedures
based on imaging and tissue biopsy [31,32]. Liquid biopsy can be used as a complementary
diagnostic tool for the study of breast cancer, and it is a promising concept in oncology to
investigate tumour heterogeneity, dynamics and progression [33–35]. Through the analysis
of circulating biomarkers, such as CTCs (circulating tumour cells), ctDNA (circulating
DNA) and extracellular vesicles (EVs), liquid biopsy has the potential to access genetic and
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phenotypic information about the primary and secondary tumours, allowing early diagno-
sis, accurate prognosis and personalized therapeutics [30,36–38]. CTCs are constantly shed
from the primary and/or secondary tumour into the bloodstream, and they have a short
half-life. Since they present the same phenotype and genotype as the tumour from where
they originate, their continuous analysis can provide information about the disease in
real-time, allowing a more accurate prognosis [39–41]. In addition, since the dissemination
of tumour cells is the principal mechanism for metastatic formation, the analysis of CTCs
has previously shown to be an ideal approach for early detection of metastasis [42,43].
The study of the presence of HER2 in CTCs can help in providing a more accurate prog-
nosis on the disease evolution, and therefore assist in improving the treatment strategies
that may be more effective in lowering CTC burden, reducing the possibility of metastasis
formation. Studies showed that some patients have HER2-positive CTCs, even when the
primary tumour is HER2-negative, leading to new trials in order to investigate if these
patients can benefit from anti-HER2 therapy [44,45]. However, it is not well understood
if changes in HER2 status are due to imprecise assessment of the primary tumour or to
emergence of new clones of HER2-positive cells [46]. Authors in [47] demonstrated that
by using trastuzumab as secondary adjuvant treatment, HER2-positive CTCs were elimi-
nated in patients with HER2-negative primary tumour. The TREAT CTC trial, in which
1317 patients with HER2-negative primary tumour and high levels of CTCs even after
neoadjuvant chemotherapy received trastuzumab therapy for 18 weeks, concluded that
CTC-based screening is possible in early breast cancer. In addition, it was observed that
CTC+ patients presented a higher risk of relapse, and that trastuzumab has no effect on
CTCs in HER2- BC [48]. The NSABP B-47 trial supports and confirms this finding, in which
trastuzumab has shown to be inefficient in 3270 patients [45,49–52]. More recent studies,
using liquid biopsy systems, have proven able to isolate HER2+ CTCs from breast cancer
patients with HER2+ or HER2- tissue biopsy [53]. However, studies to date have failed
mainly due to the reduced number of CTCs found in patient samples [54]. CTCs are indeed
rare, and their technical isolation is challenging; hence, their application in the clinic has
been limited [37,55].
Despite all the methods and technologies available, the CellSearch® system is the
only platform for enumeration of CTCs approved by the Food and Drug Administration
(FDA) to date [56–58]. CellSearch® was designed for the immunomagnetic enrichment,
fluorescent labelling and detection of CTCs [57]. Despite the demonstrated clinical validity
of CellSearch®, its enrichment method causes cell loss affecting the sensitivity of the system.
Furthermore, it only selects CTCs expressing EpCAM; thus, other CTC phenotypes are
missed, such as mesenchymal and stem cell-like tumour cells that have low levels or no
EpCAM expression [58–60].
Microfluidics is a technology capable to manipulate fluids using micrometre sized
channels [61]. Microfluidic-based separation methods are an attractive alternative to tradi-
tional cell isolation technologies due to the use of small sample and reagent volumes with a
reduced cost, low contamination issues and no sample-processing steps. By taking advan-
tage of these features, cell loss in samples with low cell concentration can be also reduced,
resulting in superior sensitivity and enhanced cell recovery [61–64]. Several microfluidic
devices have been developed for CTCs isolation showing high efficiency. Microfluidic
enrichment systems can be classified into two major groups. One group is composed of
affinity-based methods, based on positive or negative immune selection; however, these
methods end up lacking specialization, since CTCs may not express the biomarkers in use.
The other group is based on the physical properties of the CTCs, mainly size-based meth-
ods [64–66]. Since CTCs are physically distinct from blood cells in many characteristics,
including, size and deformability, microfluidic chips for CTC isolation can be made using
structures of different geometries for size-based cell filtering.
Among the many size-based methods, it is possible to highlight some such as hydro-
dynamic and cross-flow filtration, inertial focusing microfluidic systems and systems based
on shear-induces diffusion [67–70]. In the well-known method of inertial microfluidics,
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the hydrodynamic forces of a fluid are used in the channel in order to focus particles or
cells in specific equilibrium positions in a section of the channel, in this case, CTCs [69,71].
Since inertial forces are highly size-dependent, larger cells migrate faster into equilibrium
positions, getting on focus, differently from smaller cells [68]. In a more recent size-based
method, whole blood was introduced directly in the chip and separated by a buffer flow,
and this arrangement triggers the effect of shear-induced diffusion (SID). This effect, allows
larger cells to migrate faster into the buffer flow, isolating CTCs from whole blood [69,72].
Several technologies for size-based CTC isolation have been reported with various
geometries showing high efficiency. The Vortex chip (Vortex Biosciences) demonstrated
high purity (57–94%) but low capture efficiency (up to 37%) of spiked MCF7 breast cancer
cells when using diluted blood [73,74]. The ParsortixTM platform (ANGLE) showed an
isolation efficiency up to 70% in spiking experiments with cells of a large size; however,
among other disadvantages, this system yields low CTC purity (3.1%) [75].
Our group has previously developed and validated different microfluidic devices for
the rapid isolation of unfixed CTCs with high efficiency and purity in colorectal and bladder
cancer [32,76,77]. The CROSS chip captured CTCs based on their size and deformability
with an efficiency of 70% [32]. CTCs were detected in all patient samples and were not
observed in the blood of healthy individuals [32,76,77]. Improving on the performance of
previously developed systems, our technology processed 7.5 mL of whole blood in just
47 min with enhanced efficiency and purity [32,78].
Due to the numerous advantages of this technology, we designed a study to determine
the presence of HER2+ CTCs in a cohort of MBC patients. In parallel, and in order to en-
hance the compatibility of the system with conventional downstream analysis techniques,
the chip was redesigned to fit onto a conventional glass slide. This new generation, the
RUBYchip™, was optimised for the processing of breast cancer samples and improved the
isolation of breast CTCs based on their size and deformability. The performance of the
system was compared blind with the gold standard CellSearch®. Finally, the relevance
of HER2+ CTCs was studied following the clinical evolution of patients, demonstrating
the validity of our system and the overall impact of the implementation of liquid biopsy
for patient monitoring, delivering accurate, real-time prognosis and enabling personal-
ized treatment.
2. Results
2.1. RUBYchip™ Performance Assessment Using Human BC Cell Lines
In order to assess the capture efficiency of the RUBYchipTM for the isolation of breast
cancer cells with different phenotypes, human peripheral whole blood samples from
healthy donors were spiked with 200 Hoechst-stained cultured cells and processed through
the microfluidic chip. Spiking experiments were performed using three cell lines with
different levels of HER2 expression, namely MCF-7 (no expression of HER2), MDA-MB-435
(low expression of HER2) and SKBR3 (overexpression of HER2). In addition, four different
flow rates were tested for sample processing: 100, 120, 140 and 160 µL/min.
Since the isolation capacity of the RUBYchip™ relies on the cancer cell size and
deformability, the size and morphology of the cell lines were assessed inside the microchip.
The average size of the tested cells varied from 14 to 40 µm (MDA-MB-435 being the
smallest in size and SKR3 the largest) (Figure 1), and some events of larger dimensions
were observed, from 50 to 60 µm, possibly due to different stages of the cell cycle and
likely in mitosis. Still, within this range of cell size, there was no significant variation in the
capture efficiency across cell lines.
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Figure 1. Representative image of cells of three different cell lines trapped inside the RUBYchip™ at
the spiking assay. MCF-7, MDA-MB-435 and SKBR3 estimated sizes are 21.02, 14.45 and 37.77 µm,
respectively. The images were acquired and observed with a 20× objective. The scale bars correspond
to 50 µm.
The highest capture efficiency was achieved at 120 µL/min, consistently for all the
cell lines tested, such that the RU Ychip™ was able to isolate an average of 53%, 59%
and 56% of spiked MCF-7, MDA-MB-435 and SKBR3 breast ca cer c lls, re pectively
(Figure 2). The capture fficiency decreased in all the oth rs flow rates tested. C nsidering
these results, 120 µL/min was determined as the optimal flow rate to be used for future
processing of breast cancer patient samples. This flow rate allowed a fast sample processing,
making it possible to process 7.5 mL of whole blood in 63 min.
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2.2. Cell Staining and Analysis Criteria
In order to optimize the antibody conditions to be used for patient samples in the
RUBYchip™, several immunocytochemistry (ICC) experiments were performed in cultured
adherent cells as well as cell suspensions processed inside the microfluidic device. Negative
controls were included using samples from healthy volunteers.
The ICC experiments were carried out using MCF-7, MDA-MB-435 and SKBR3 cell
lines, as well as peripheral blood mononuclear cells (PBMCs). According to the literature,
SKBR3 cells exhibit cytoplasmatic cytokeratin (CK) expression and HER2 overexpression
in the cell membrane; MCF7 cells express CK but not HER2; MDA-MB-435 do not express
any of the selected biomarkers. PBMCs were labelled using CD45, which was used as an
exclusion criterion to evaluate CTCs [79–81].
Immunocytochemistry demonstrated that this staining cocktail can discriminate be-
tween the three different cell lines and the negative control, as follows: MDA-MB-435
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are DAPI+/CK−/HER2−/CD45−, MCF-7 are DAPI+/CK+/HER2−/CD45−, SKBR3 are
DAPI+/CK+/HER2+/CD45− and PBMCs are DAPI+/CK−/HER2−/CD45+. These re-
sults are in accordance with previous findings [82–85]. Once immunostaining specificity
was verified, the CTC classification for patient samples analysis was established as shown
in Figure 3. Once the antibody cocktail and conditions for the immunofluorescence signal
acquisition were thoroughly optimised using either culture adherent cells in a well-plate,
or a suspension of cultured cells into the device, optimal antibody dilutions were redefined
using a patient sample and established to be applied in the analysis of further patient
samples, namely 1:200 for CK, 1:106 for HER2 and 1:100 for CD45.
2.3. Patient Recruitment and Clinical Characteristics
A total of 15 eligible patients diagnosed with MBC, either de novo or after recurrence,
and followed at Hospital de Santa Maria, were recruited to participate in this study.
The patients entered the study by the end of 2018, and collections were made from that time.
The main clinicopathological characteristics of the patient cohort are presented in
Table 1. Regarding this cohort, the average age of the patients at metastases diagnosis was
47 years; 80% of those patients were less than 60 years old and 20% were 60 or older. The
longest time elapsed between the first diagnosis and the metastasis diagnosis was of 13
years (patient 6) and the shorter time was of 0 months (patient 10), with the metastasis
diagnosis coinciding with the first diagnosis, averaging 68 months until disease relapse
occurred (6 years). Metastases were found in different sites, and the highest incidence was
in visceral organs (40%), followed by bone (33.3%) present in five patients. Four patients
had metastases in multiple sites simultaneously (26.7%), namely, bone and lung (1 patient,
6.7%), lung and lymph node (1 patient, 6.7%), liver and cutaneous (1 patient, 6.7%), and
one patient had cutaneous metastases (6.7%).
The cohort can be divided into five different groups according to their breast cancer
subtype. A total of 46.7% of the patients had ER+/PR+/HER2− tumours, which is the
most common subtype, followed by ER+/PR−/HER2− occurring in 20% of the patients,
ER+/PR+/HER2+ and ER+/PR−/HER2+ occurring in 13.3% of the patients each, and
triple-negative breast cancer (ER−/PR−/HER2−) diagnosed in 6.7% of the patients. These
different subtypes of BC were included in the study so that it was possible to analyse and
cover all BC patients, as well as to analyse the presence of HER2 in the CTCs of patients
with different primary tumour subtypes. Most patients were diagnosed with disease
relapse (93.3%), but 6.7% or were diagnosed de novo with metastatic disease.
Overall cancer treatment was administrated following the institutional guidelines and
in compliance with the international oncology society guidelines.
At the moment of the first collection, most of the patients received systemic therapy, ex-
cept one patient (patient 12, with TNBC) who was treated with radiotherapy. Five patients
(33.3%) received systemic chemotherapy, and eight patients were treated with hormone
therapy (53.3%). In addition, three patients (20.0%) with HER2-positive primary tumours
were treated with anti-HER2 therapy (alone or combined with chemotherapy), and five
patients (33.3%) received cyclin inhibitor therapy combined with hormone therapy. Bone
target therapy was also administrated in four patients (26.7%) who had bone metastases.
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cell lines was spiked in healthy whole blood samples and processed in the device (bottom). MCF-7 cells stained strongly for
CK, with cytoplasm localization; SKBR3 cell membrane stained positively for HER2; most PBMCs stained for CD45. (b) For
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2.4. Isolation of CTCs Using th RUBYchip™ and CellSearch®
The performance of the RUBYchip™ using patient samples was next evaluated by
comparing this technology with the gold standard and FDA-approved system for CTCs
enumeration in the clinic, CellSearch®.
For each patient, two tubes of 7.5 mL of peripheral blood were collected and processed
in parallel using either technology. Collection for each patient took place at two time
points: at baseline, before starting systemic treatment, and at monitoring follow-up, after
12 weeks of ongoing treatment. After cell isolation, a randomized blind sample analysis was
performed, and results obtained from both technologies were compared. In order to reduce
inter-laboratory variability in CTC enumeration and provide validation against the gold
standard methodology, all CTC image galleries produced by the analysis of RUBYchip™
were also independently interrogated by a highly experienced operator, responsible for a
liquid biopsy unit at a reference laboratory.
The number of CTCs identified by the RUBYchip™ and the CellSearch® were com-
pared head-to-head including all 30 samples, without discrimination of time-points. In ad-
dition, to further investigate the CTC count evolution and its association with disease
progression, baseline and follow-up collections were compared for each patient.
The cells isolated between pillars of the microfluidic device were stained with Anti-
Cytokeratin pan-FITC, Cyanin5 Anti-Human CD45, DyLight 550 Anti-ErbB2/HER2 and the
nuclear dye DAPI. Only DAPI+/CK+/CD45−/HER2+ and DAPI+/CK+/CD45−/HER2−
cells were considered CTCs (Figure 4b). These trapped cells’ estimated cell size range was
from 7.93 µm to 18.50 µm (Figure 4a).
Cancers 2021, 13, 4446 8 of 26




Number of patients 15 –
Number of collections 30 –
Sex
Female 15 100
Age at MBC diagnosis (years)
Average (range) 47 (29–65)
≥60 years 3 20.0


















Visceral c 6 40.0
Bone 5 33.3
Multiple/other 4 26.7
Treatment initiated at baseline d
Including Chemotherapy 5 33.3
Including Hormone therapy 8 53.3
Including HER2-targeted therapy 3 20.0
Including other targeted therapy 5 33.3
Radiotherapy only 1 6.7
MBC diagnosis at inclusion
Relapse 14 93.3
De novo 1 6.7
Vital Status, at conclusion
Alive with metastatic disease 15 100
CTC positive, at baseline
RubychipTM 15 100
CellSearch® 7 46.7
CTC positive, at follow up e
RubychipTM 14 93.3
CellSearch® 4 26.7
a. HER2 status at the time of study inclusion; b. No information was available from the metastasis, and the subtype was derived by
staining of the primary tumour; c. Visceral metastasis defined as lung, liver, brain, lymph nodes, peritoneal and/or pleural involvement; d.
Treatment initiated = first or new line of treatment initiated at baseline collection; e. clinical follow up at 3 months after baseline.
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The comparative study of the 30 MBC samples demonstrated considerable differences
between both technologies in CTC enumeration. The average number of CTCs isolated
by the RUBYchip™ at baseline and follow-up samples was 12 and 8, respectively, in
considerable contrast to the CellSearch®, which isolated an average of 2 CTCs at baseline
and none at follow-up samples (Figure 5). Overall, RUBYchipTM was able to isolate CTCs
with higher efficiency than CellSearch®, up to 10 times more, averaging all 30 samples
(p < 0.0002, Wilcoxon test). Strikingly, the RUBYchip™ was able to detect CTCs in 97%
of all 30 samples examined as opposed to only 37% on CellSearch®, which indicated the
superior efficiency of the first. In addition, considering the threshold established for po r
disease progression at 5 or more CTCs, the CellS arch® counts were below 5 for 26 of th
samples (87%), while he RUBYchip™ counted a l ast 5 CTCs in 21 of the samples (70%),
allowing more accurat evaluation of the disease prognosis for each patient (Table 2).









Figure 5. (a) Comparative scatterplot demonstrating the enumeration of CTCs using the RUBYchip™, in light grey versus
the CellSearch® system, in dark grey, for all the 30 samples analysed. (b) Representative images of captured cells using
both technologies. CellSearch® on the bottom, and RUBYchip™ on the top. RUBYchip™ technology allows to obtain
high-resolution images, and image quality is clearly superior when compared to CellSearch®. Isolated cells trapped
between pillars of the RUBYchip™ were stained with Anti-Cytokeratin pan-FITC, Cyanine5 Anti-Human CD45, DyLight
550 Anti-ErbB2/HER2 and the nuclear marker DAPI.
Table 2. Results of the CTC count using RUBYchip™ versus CellSearch®.
Baseline (n = 15) Follow-Up (n = 15) Overall (n = 30)
RUBYchip™ CellSearch® RUBYchip™ CellSearch® RUBYchip™ CellSearch®
CTCs/7.5 mL
Average 12 2 8 0 10 1
Median 6 0 6 0 6 0
N◦ of cases
CTC + 15 (100%) 7 (47%) 14 (93%) 4 (27%) 29 (97%) 11 (37%)
CTC ≥ 5 12 (80%) 3 (20%) 9 (60%) 1 (7%) 21 (70%) 4 (13%)
CTC < 5 3 (20%) 12 (80%) 6 (40%) 14 (93%) 9 (30%) 26 (87%)
Representative immunofluorescence micrographs of CTCs from both the CellSearch®
and the RUBYchip™ are presented in Figure 5. As shown, image quality obtained with the
RUBYchip™ technology considerably improved compared to CellSearch®, allowing for
easier, faster and more reliable analysis
2.5. HER2 Status Assessment Using Liquid Biopsy and Tissue Biopsy
HER2 is an established therapeutic target in breast cancer; hence, adequate use of targeted
therapy depends on accurate assessment of HER2 status. To further evaluate the value
of the HER2 analysis in CTCs isolated using a microfluidic approach, as a tool for a real-
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time diagnosis and follow-up, the presence of HER2-positive CTCs in the patient samples
was assessed by both technologies. Besides HER2+ CTCs (DAPI+/CK+/HER2+/CD45−)
enumeration by RUBYchip™ and CellSearch®, liquid biopsy findings were compared with the
histopathological assessment of HER2 status from the tissue biopsy of the primary tumour
(Figure 6). DAPI+/CK−/HER2+/CD45− events were not considered for CTC enumeration.
Overall, also in the detection of HER2-positive CTCs, RUBYchip™ was consider-
ably more efficient, as it was able to isolate HER2+ CTCs in nine patients (60%), while
CellSearch® only did in four patients (26.7%). It is noteworthy to mention that results
obtained with the RUBYchip™ were in agreement with tissue biopsy assessment of HER2
expression in the majority of cases at the baseline analysis, 14/15 patients (93.3%), which is
the closest time-point to the tissue biopsy. In opposition, CellSearch® was largely unable
to confirm or refute tissue biopsy HER2 status assessment at baseline, since it yielded
inconclusive results (no CTCs) in eight cases (over 50%), additionally differed regarding
two patients and agreed in 5 patients only. Moreover, at follow-up collection, rate of
inconclusive HER2 testing with CellSearch® increased to 73.3%, as the technology was not
able to detect any CTC in 11 of the 15 patients. The low efficiency of CellSearch® or the
presence of CTCs with low expression of EpCAM were assumed to be accountable for such
results. In total, CellSearch® was unable to detect over 1 HER2+ CTC per sample, while in
contrast RUBYchip™ was able to detect on a range of 1 to 11 HER2+ CTCs.
Interestingly, results from both technologies combined demonstrate that liquid biopsy
is able to detect more HER2 positivity cases than the tissue-based approach; 11 patients
had HER2+ CTCs detected (73.3%) as opposed to 4 patients that tested positive for HER2 in
primary tumour tissue assessment (26.7%). This result might be indicative of the sampling
limitations in conventional tissue biopsy that fails to reflect tumour heterogeneity, or simply
due to disease progression.
Easily repeatable sampling for frequent monitoring is an accepted advantage of liquid
biopsy to access therapeutic resistance and base decision-making during treatment cycles.
Interestingly, the group of patients (Patients 1, 4, 8 and 10) diagnosed as having HER2+
tumours that were subjected to anti-HER2 therapy, in between the two moments of blood
collection, were confirmed positive for HER2+ CTCs at the baseline; however, they showed
no HER2+ CTCs at the follow-up, suggesting the success of the anti-HER2 targeted therapy.
In contrast, CellSearch® only detected HER2+ CTCs in one of these four patients.
2.6. Correlation of Clinicopathological Information with CTC Enumeration and Characterisation
To further evaluate the implications of CTC analysis in MBC setting, it was evalu-
ated whether CTC enumeration and HER2 status findings were associated with relevant
clinicopathological characteristics, including BC subtype, HER2 status in primary tumour,
administrated treatment/therapeutic options and clinical stage.
It was observed how the number of isolated CTCs evolved during the course of the
disease, taking into account the therapy administered in the elapsed time. The number
of CTCs isolated by either technology in the 15 metastatic breast cancer patients at the
two time points is presented in Table 3. Considering the RUBYchip™ results, five patients
(33.3%) had increased CTC counts at follow-up when compared to the baseline collection,
namely, patients 1, 6, 11, 12 and 13. HER2+ CTCs were detected by the RUBYchip™ in
patients 1 and 13, as referred in the previous section. Patient 1, which was diagnosed
as having a HER2+ tumour, received anti-HER2 therapy after baseline collection and,
although an increase in the total number of CTCs was observed, the number of HER2-
positive CTCs decreased. Patient 13 was diagnosed as having a TNBC tumour and had
an increase of 18 CTCs at follow-up (3× higher than baseline). A considerable increase in
the total number of CTCs at follow-up was also observed in patients 11 and 12, this last
one with TNBC, who did not receive systemic therapy. All the other patients showed a
decrease in the number of total CTCs. Most noticeable cases of decreased number of CTCs
at follow-up, compared to baseline, were observed in patients 3 (26× less CTCs), 4 (from
24 to 0 CTCs) and 5 (from 17 to 0 CTCs).
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Figure 6. Representative scheme on the HER2 expression status on the primary tumour by tissue biopsy and on the CTCs 
at two different collection time-points, baseline (before starting systemic therapy) and follow-up (after 12 weeks of sys-
temic treatment), by both technologies, RUBYchip™ and CellSearch® . The HER2+ CTC events are represented in orange, 
HER2− CTC in grey, and in white no CTCs were isolated. The number of HER2+ CTCs is represented at the respective 
collection moment, for each technology. 
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Figure 6. Representative scheme on the HER2 expression status on the primary tumour by tissue biopsy and on the CTCs at
two different collection time-points, baseline (before starting systemic therapy) and follow-up (after 12 weeks of systemic
treatment), by both technologies, RUBYchip™ and CellSearch®. The HER2+ CTC events are represented in orange, HER2−
CTC in grey, and in white no CTCs were isolated. The number of HER2+ CTCs is represented at the respective collection
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Table 3. Number of CTCs isolated by the RUBYchip™ and the CellSearch® in the 15 metastatic breast




Baseline Follow-Up Baseline Follow-Up
1 15 23 2 1
2 4 2 0 0
3 26 1 1 0
4 24 0 0 0
5 12 1 7 0
6 5 7 0 1
7 6 3 0 0
8 6 1 0 0
9 28 10 0 0
10 6 6 28 56
11 3 15 1 0
12 3 12 0 0
13 5 20 1 1
14 25 14 13 0
15 6 6 0 0
2.7. Prognostic Value of CTC Enumeration
To assess the prognostic value of CTCs counts in this cohort, th 15 enrolled patie ts
were divided in o baselin CTC < 5 and CTC ≥ 5 groups, which is the established t reshold
o prognostic favourable and unfavourable CTC-coun s in mBC a cording to the FDA
approved procedure. Kaplan–Meier survival curv s to determine the PFS and OS for the
two groups using both CTC isolation technologies are shown in Figure 7. Out of the 15
patients, 80% had ≥5 CTCs detected using the RUBYchip™, whereas only 20% had been
detected using CellSearch®.
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Figure 7. Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) according to CTC count (≥5 
CTCs/7.5 mL of blood), using (a,b) RUBYchip™ and (c,d) CellSearch®  for isolation of CTC in MBC patients. PFS and OS 
were calculated from the time of the baseline blood collection. Differences in survival curves were determined using the 
log-rank test. 
Regardless of the isolation methodology, overall survival curves plateaued above 
50% risk of survival, and sharp decreases to the probability of survival were observed 
only by the end of the study, indicating that a substantial proportion of patients survived 
for longer than the follow-up period, throughout the study. Although it may be indicative 
that there are very few patients at high risk at baseline, this small and heterogeneous co-
hort limits our ability to reach significant results based on one single time point. Never-
theless, accounting for CTC enumeration across the two time-points, the population was 
dichotomized as favourable when CTC counts were (i) below 5 CTCs at baseline and fol-
low-up or (ii) above 5 CTCs at baseline, but below 5 CTCs at follow-up; and unfavourable 
when (i) above 5 CTCs at baseline and follow-up or (ii) below 5 CTCs at baseline, but 
above 5 CTCs at follow-up. The CellSearch®  detection method was not able to discriminate 
subpopulations in this cohort, since only a single patient was considered to have unfa-
vourable CTC counts. Out of the 15 patients, using the RUBYchip™, discrimination of 
populations was well-defined with 40% that had favourable prognostic CTC counts and 
60% with unfavourable CTC counts. Although no significant association between distinct 
subpopulations detected by RUBYchip™ and the survival measures was found (p = 
0.3718, LogRank test), patients showing unfavourable CTC counts tended to have de-
creased survival (Figure 8). 


























































































































Figure 7. Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) according to CTC count (≥5
CTCs/7.5 mL of blood), using (a,b) RUBYc ip™ and (c,d) CellSearch® for isolation of CTC in MBC patients. PFS and OS
were calculated from the time of the baseline blood collection. Differences in survival curves were determined using the
log-rank test.
Regardless of the isolation methodology, overall survival curves plateaued above 50%
risk of survival, and sharp d creases to the probability of survival were observed only by
the end of the study, indicating that a substantial proportion of patients survived for longer
than the follow-up period, throughout the study. Although it may be indicative that there
are very fe patients at high risk at baseline, this small and heterogeneous cohort limits our
ability to reach significant results based on one single time point. Nevertheless, accounting
for CTC enumeration across he two time-points, the population was dichotomized as
favourable when CTC counts were (i) below 5 CTCs at baseline and follow-up or (ii) above 5
CTCs at baseline, but below 5 CTCs at f llow-up; and unf vourable when (i) above 5 CTCs
at baseline and follow-up or (ii) below 5 CTCs at baseline, but above 5 CTCs at follow-up.
The CellSearch® detection method was not able to discriminate subpopulations in this
cohort, since only a single patient was considered to have unfavourable CTC counts. Out
of the 15 patients, using the RUBYchip™, discrimination of populations was well-defined
with 40% that had favourable prognostic CTC counts and 60% with unfavourable CTC
counts. Although no significant association between distinct subpopulations detected by
RUBYchip™ and the survival measures was found (p = 0.3718, LogRank test), patients
showing unfavourable CTC counts tended to have decreased survival (Figure 8).




Figure 8. Kaplan–Meier curves of progression-free survival (PFS) according to favourable or unfa-
vourable CTC count (cut-off of <5 or ≥5 CTCs CTCs/7.5 mL of blood in both time points—baseline 
and follow-up collection), using RUBYchip™ to isolate CTCs in MBC patients. Progression-free sur-
vival was calculated from the time of the baseline blood collection. Differences in survival curves 
were determined using the log-rank test. 
2.8. Prognostic Value of HER2 Status in CTCs 
HER2 status in CTCs was assessed across two time points; both baseline and follow-
up collections were considered to dichotomize the population as concordant or discordant 
in relation to the molecular subtype assessed in tissue biopsy. The concordant subpopu-
lation is in agreement with molecular subtyping performed on the primary tumour tissue, 
in both collections. The discordance in HER2 status was established considering a CTC 
HER2 status different from HER2 tissue assessment in at least one collection, with equal 
or over 50% in HER2 CTCs/Total CTCs ratio. 
Using RUBYchip™ technology, concordance in HER2 status between CTCs and tis-
sue biopsy was observed in 60% of the patients and discordance in 40%. Similarly, using 
CellSearch® , 53% of patients were found to be concordant and 47% discordant from tissue 
assessment. However, survival analysis showed no prognostic impact of the subpopula-
tions detected by the CellSearch® , while the discordance of HER2 status in the tissue and 
the CTCs isolated with RUBYchip™ was associated with decreased PFS and OS (p = 0.4703 
and p = 0.0399, respectively, using the log-rank test), as shown in Figure 9. Of note, this 
prognostic association was particularly significant for predicting OS, and it shows that 
patients considered discordant using the RUBYchip™ presented decreased OS, suggest-
ing this technology enables discrimination of risk populations and its potential as a prog-
nostic tool, even though the population size was limited. 
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Figure 8. Kaplan–Meier curves of progression-free survival (PFS) according to favourable or un-
favourable CTC count (cut-off of <5 or ≥5 CTCs CTCs/7.5 mL of blood in both time points—baseline
and follow-up collection), using RUBYchip™ to isolate CTCs in MBC patients. Progression-free
survival was calculated from the time of the baseline blood collection. Differences in survival curves
were determined using the log-rank test.
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2.8. Prognostic Value of HER2 Status in CTCs
HER2 status in CTCs was assessed across two time points; both baseline and follow-up
collections were considered to dichotomize the population as concordant or discordant in
relation to the molecular subtype assessed in tissue biopsy. The concordant subpopulation
is in agreement with molecular subtyping performed on the primary tumour tissue, in
both collections. The discordance in HER2 status was established considering a CTC HER2
status different from HER2 tissue assessment in at least one collection, with equal or over
50% in HER2 CTCs/Total CTCs ratio.
Using RUBYchip™ technology, concordance in HER2 status between CTCs and tissue
biopsy was observed in 60% of the patients and discordance in 40%. Similarly, using
CellSearch®, 53% of patients were found to be concordant and 47% discordant from tissue
assessment. However, survival analysis showed no prognostic impact of the subpopula-
tions detected by the CellSearch®, while the discordance of HER2 status in the tissue and
the CTCs isolated with RUBYchip™ was associated with decreased PFS and OS (p = 0.4703
and p = 0.0399, respectively, using the log-rank test), as shown in Figure 9. Of note, this
prognostic association was particularly significant for predicting OS, and it shows that
patients considered discordant using the RUBYchip™ presented decreased OS, suggesting
this technology enables discrimination of risk populations and its potential as a prognostic
tool, even though the population size was limited.




Figure 9. Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) according to concordant or 
discordant HER2 status of CTC in relation to primary tissue assessment, using RUBYchip™ (a,b) and CellSearch®  (c,d) to 
isolate CTCs in MBC patients. PFS and OS were calculated from the time of the baseline blood collection. Differences in 
survival curves were determined using the log-rank test. 
3. Discussion 
The RUBYchip™ has demonstrated a high capture efficiency (56% on average) at 120 
μL/min, using breast cancer cell lines. This is due to its distinctive ability to directly filter 
CTCs from unprocessed whole blood samples, as well as the design features of the micro-
fluidic chip, namely the pre-filters layout, prevented flow obstructions by eventual cell 
debris or microclots. The geometry of the RUBYchip™, along with its surface treatment, 
creates a favourable environment for CTC entrapment, eliminating most of the blood cells, 
such that a compromise between efficiency, speed and purity is obtained. The chip dimen-
sions are ideal to allow deformable cells, generally blood cells, to pass through the filter 
gaps; however, cells that cannot deform, due to the smaller cytoplasm-to-nucleus ratio, 
are retained. These larger cells with bigger nucleus and cytoplasm are more likely to get 
trapped [86]. CTCs may have a wide range of cell sizes and phenotypes [87], as assessed 
using three cell lines different in cell size and phenotype aimed at testing a reliable repre-
sentation of CTCs in circulation in clinical samples. This helps us better understand the 
capacity of the size-based filter to isolate CTCs, guaranteeing a compromise between cell 
isolation efficiency and purity at the best flow rate, despite the morphological differences 
that exist [86]. Despite cytomorphological differences between cell lines analysed, the re-
sults obtained were consistent for all the flow rates tested, and similar isolation efficiency 
values were observed for all the different cell lines. Moreover, the miniaturized chip size 
(fitting within a standard 25 × 75 mm glass slide) enables streamlined device fabrication 
and microscopy imaging. 
Preclinical validation of the RUBYchip™ was achieved through a comparative study 
between our chip and the CellSearch®  system, the only FDA-approved technology for 
CTC enumeration. Side-by-side comparison of both technologies shows that RUBYchip™ 
consistently captured much more CTCs than CellSearch® , up to 10 times more, overall 
averaging 30 samples. The noticeable discrepancies in the number of CTCs isolated by the 
two different systems, in most of the samples (Figure 3), can be explained by the fact that 
the CellSearch®  system targets EpCAM+ CTCs only, missing out other CTCs with low 


























































































































Figure 9. Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) according
to concordant or discordant HER2 status of CTC in relation to primary tissue assessment, using
RUBYchip™ (a,b) and CellSearch® (c,d) to isolate CTCs in MBC patients. PFS and OS were calculated
from the time of the baseline blood collection. Differences in survival curves were determined using
the log-rank test.
3. Discussion
The RUBYchip™ has demonstrated a high captu fficiency (56% average) at
120 µL/min, using brea t can er cell lines. This is due to its distinctive ability to di ctly
filter CTCs from unprocessed whole blood samples, as well as the design features of the
microfluidic chip, namely the pre-filters layout, prevented flow obstructions by eventual
cell debris or microclots. The geometry of the RUBYchip™, along with its surface treatment,
creates a favourable nvironment for CTC entrapme t, liminating most of the b ood
cells, such that a compromise between efficiency, speed and purity is obtained. The chip
dimensions are ideal to allow deformable cells, generally blood cells, to pass through the
filter gaps; however, cells that cannot deform, due to the smaller cytoplasm-to-nucleus
ratio, are retained. These larger cells with bigger nucleus an cy oplasm are more likely
to get trapped [86]. CTC may have a wide ran e of cell sizes and phenotypes [87], as
assessed using three cell lines different in cell size and phenotype aimed at testing a reliable
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representation of CTCs in circulation in clinical samples. This helps us better understand
the capacity of the size-based filter to isolate CTCs, guaranteeing a compromise between cell
isolation efficiency and purity at the best flow rate, despite the morphological differences
that exist [86]. Despite cytomorphological differences between cell lines analysed, the
results obtained were consistent for all the flow rates tested, and similar isolation efficiency
values were observed for all the different cell lines. Moreover, the miniaturized chip size
(fitting within a standard 25 × 75 mm glass slide) enables streamlined device fabrication
and microscopy imaging.
Preclinical validation of the RUBYchip™ was achieved through a comparative study
between our chip and the CellSearch® system, the only FDA-approved technology for
CTC enumeration. Side-by-side comparison of both technologies shows that RUBYchip™
consistently captured much more CTCs than CellSearch®, up to 10 times more, overall
averaging 30 samples. The noticeable discrepancies in the number of CTCs isolated by
the two different systems, in most of the samples (Figure 3), can be explained by the fact
that the CellSearch® system targets EpCAM+ CTCs only, missing out other CTCs with low
EpCAM expression. Loss of CTCs during sample processing steps is also to be accountable,
while whole-blood samples are introduced and filtered directly processed directly into the
RUBYchip™, decreasing the possibility of cell loss.
In addition to the detection of epithelial-like CTCs (DAPI+/CK+/CD45−), DAPI+/CK−/
CD45−/HER2+ cells were identified in the RUBYchip™, suggesting that this device is able to
isolate cells with different phenotypes, increasing even further the number of isolated CTCs and
providing additional important information of the disease status. In fact, other studies described
the isolation of CK−/HER2+ CTCs in breast cancer recurring to liquid biopsy systems [53].
In previous clinical trials, using the CellSearch® system, a threshold to distinguish
patients with shorter progression-free survival and overall survival was established at
≥5 CTC/7.5. mL of blood [56]. In this study, 26 (86.7%) of the samples analysed by the
CellSearch® led to a classification of the patients as having good prognosis, since the
number of CTCs was below the threshold. In contrast, the RUBYchip™ detected CTCs
above the cut-off in 21 (70%) of the samples.
The fact that most of the patient samples analysed using CellSearch® had a number of
CTCs below threshold could lead to a misleading classification of the patients as having
good prognosis; however, when comparing with the RUBYchip™ system, it was possible
to observe that the same patient samples had a much higher number of CTCs, meaning that
a misleading assumption concerning prognosis could have been made using CellSearch®.
Even though the thresholds for each technology may differ, the results showed that the
RUBYchip™ had a much better performance and allowed a more trustworthy evaluation
of the CTC burden and, potentially, patient prognosis.
HER2 is an established therapeutic target in breast cancer. As such, screening its
presence in CTCs provides information of great utility for therapeutic reasoning. Hence, the
presence of HER2-positive CTCs in the patient samples was assessed by both technologies,
and findings on CTC HER2 status were compared with the HER2 status of the tissue
biopsy sample. Regarding the technologies in study, the results showed that not only was
the RUBYchip™ able to isolate and detect HER2+ CTCs in a higher number of samples
(9 patients in the RUBYchip™ against 4 patients in the CellSearch®), but also the number
of HER2+ CTCs captured was higher, with an average of 2.6 CTCs, whereas the average
number of HER2+ CTCs isolated by CellSearch® was 1, proving once again that RUBYchip™
has a better performance.
The clinical reports on tissue biopsy analysis reported that four patients were diag-
nosed as having HER2+ tumours, and they were treated with anti-HER2 targeted therapy
between the two time points. In these cases, tissue biopsy was made at the time of the
primary diagnosis, which in some of these patients occurred several years before this study
and may reflect an inaccurate assessment of the real-time HER2 status. The RUBYchip™
found HER2+ CTCs in all four patients with HER2 expression detected by tissue biopsy,
while the CellSearch® detected these cells in only one patient. It is important to mention
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that liquid biopsy analyses were performed blindly from the patients’ clinicopathological
characteristics. Consensus among the three methodologies was found only in one patient
(patient 1). The agreement between RUBYchip™ analysis and tissue biopsy classification
supports the importance of CTCs isolation and characterization, to allow accurate diagnosis
and subtype classification in real-time for successful therapy selection.
Since our results show that the number of HER2+ cells decreased between times of
collection in patients under anti-HER2 targeted therapy, it may suggest a positive response
to therapy. The higher number of CTCs in total by one of the patients (patient 1) may be
indicative that the tumour burden is still high, but tumour phenotypical characteristics
have changed, ideally even to a less invasive and more well managed subtype [88,89]. The
presence of HER2+ cells, isolated by the RUBYchip™, in patients that were not diagnosed
as having HER2+ tumours by the tissue biopsy analysis was observed. As mentioned in
the introduction, cancer is a dynamic and heterogeneous disease [2]; hence, the molecular
characteristics of the tumours can change over time due to therapeutic intervention or
clonal evolution. As such, patients diagnosed with Luminal A (patients 2, 3, 7 and 9) or
TNBC (patient 13) tumours could have suffered alterations over time, presenting HER2+
cells in the current collections as detected by the RUBYchip™. Additionally, it has been
discussed that HER2 testing on the tissue biopsy in some circumstances may be unreliable
or unrepresentative of the tumour [90]. It could be argued that these patients may have
harboured HER2+ overexpression in the primary tumour; however, since the biopsy is
performed to a small part of the tumour, it might not reflect the intratumour heterogeneity,
and the presence of HER2 could have been missed. Tumour misclassification imposes risks
to the patients, including decreased progression-free survival and overall survival [90,91].
Furthermore, to evaluate the role of CTCs in metastatic breast cancer, the correlation
of CTC number and HER2 status with disease progression was studied. Five patients
(33.3%) had increased CTC counts at follow-up collection. Patient 13, diagnosed with
TNBC, increased his CTC counts three times. This increase can be an indicator of a possible
resistance to therapy and worst prognosis. Patient 12, also diagnosed with TNBC and
with metastases in the central nervous system, was only treated with radiotherapy and
presented a considerable increase in CTCs. The increase in the number of CTCs between
collections may be explained by the fact that brain metastases are the most aggressive and
difficult to treat, correlated with a worst prognosis [92]. According to the clinical evaluation,
regarding the disease progression and obtained from the CT/MRI scan, none of the patients
had disease progression at the date of this submission (17 months after the first patient
was recruited). Despite presenting a small cohort and a short follow-up, which did not
allow a more longitudinal assessment of the patient’s evolution, the RUBYchip™ results
showed that some patients had increased numbers of CTCs at the follow-up, which may
be indicative of disease progression and worst prognosis. This hypothesis is in agreement
with previous reports highlighting that liquid biopsy can provide information on disease
progression even 1 year earlier than standard technologies used to monitor patients in
the clinic [30]. Lastly, although the study involves a limited cohort of patients, CTC
survival analysis results strengthen existing evidence reporting changes to HER2 status
during the clinical course of metastatic BC. Most importantly, these results reinforce the
need to use longitudinally collected samples to dynamically evaluate the heterogeneity of
disease by HER2 status in CTCs, for which tissue sampling still bears several limitations, as
opposed to the real-time CTC repetitive sampling. Additionally, the sensitivity of the CTCs
detection method is important to enable discrimination of patient populations that present
a poor evolution of the disease, since low-sensitivity technologies miss the opportunity to
distinguish prognostic groups and therefore fail to contribute to the clinical management
of patients, including treatment redirection.
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4. Materials and Methods
4.1. Microfluidic Device Design and Fabrication
The RUBYchip™ is the fourth generation (following the CROSS chip [32]) of a mi-
crofluidic system that comprises an inlet and an outlet flow channel and is designed to
split the blood equally in 2 different areas, each area displaying 4 separated modules that
are 17.5 mm wide; these have the capacity to process a total of 7.5 mL of blood.
Each module has in its middle section a plurality of anisotropic micropillars layout
in a single row, with 25 µm diameter and interspaced in about 5 µm, thereby forming a
plurality of gaps which form the cell filtering area. The size, geometry and aspect ratio
of the micropillars, as well as the gap size, were carefully chosen to allow blood cells to
deform and gently flow through, retaining, however, larger and more rigid cells in the
filter. Additional pre-filters are part of the design, and these have 120 µm gaps to prevent
clumps or debris from blocking the device. Each microfluidic device holds an approximate
internal volume of 50 µL (Figure 10).




Figure 10. The RUBYchip™ is designed to capture CTCs based on physical properties such as size 
and cellular deformability. Filtering areas are composed by interspaced micropillars, distanced from 
each other in 5 µm. 
The microfluidic masters were designed in 2D AutoCAD software (Autodesk Auto-
CAD 2020, Autodesk inc., CA, USA) and fabricated in a 200 mm silicon wafer using pho-
tolithography and deep reactive ion etching. Briefly, the silicon wafer (P/Boron, <100>, 
Siegert Wafer GmbH, Aachen, Germany) was patterned using a Direct Write Laser system 
(DWL 2000 Heidelberg Instruments, Heidelberg, Germany). The pattern was then etched 
with sulphur hexafluoride (SF6, Sigma Aldrich/ Merck KGaA, Darmstadt, Germany) by 
Silicon Deep Reactive Ion Etching (SPTS Pegasus, SPTS Technologies Ltd., Newport, Eng-
land). Trench depth was measured in between steps using an optical profilometer (Hype-
rion, OPM profilometer, OPM Messtechnik GmbH, Ettlingen, Germany) until 20 μm 
depth was reached. Residues were stripped using oxygen plasma, and the master was 
characterized by Scanning Electron Microscopy (NovaNanoSEM, FEI, Oregon, USA). Fi-
nally, the wafer was diced (Automatic Dicing Saw, DAD3350, DISCO HI-TEC FRANCE 
SARL, Gardanne, France) into the individual masters, cleaned with isopropyl alcohol 
(IPA, Sigma Aldrich) and deionized water and dried at 150 °C on a hot plate. 
Before replication, the masters were hydrophobized with a vapor-phase treatment in 
trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma Aldrich) for two hours (one hour at 
65 °C). 
After hydrophobization, for rapid prototyping using soft lithography, polydime-
thylsiloxane prepolymer was mixed with a cross-linker (PDMS, SYLGARDTM 184 Silicone 
Elastomer, Dow Chemical Company, Ellsworth Adhesives, Madrid, Spain) at 10:1 ratio, 
degassed, and poured over the master and cured at 65 °C for 2 h. Subsequently, the PDMS 
replica was unmoulded, and both inlet and outlets were punched. Finally, microscope 
glass slides (size 25 × 75 mm, ThermoFisher Scientific, Darmstard, Germany) and the 
PDMS replicas were treated with oxygen plasma (Plasma Cleaner PDC-002-CE, Harrick-
Plasma, NY, USA) to produce irreversible bonding. 
To conclude the device preparation, the chips were connected to a syringe pump 
(NE-1200, New Era Syringe Pumps, Tecan France, Lyon, France) and filled with 350 μL of 
ethanol (Sigma Aldrich) at 100 μL/min, 350 μL of 10 mM phosphate buffer saline (PBS, 
Sigma Aldrich) at 120 μL/min, and 4000 μL of 1% Pluronic F-127 (Sigma Aldrich) at 140 
μL/min for coating and preventing cell attachment onto the channel surface. 
4.2. Optimization Studies 
4.2.1. Cell Culture and Spiking Experiments 
The human cancer cell lines MCF-7 (ATCC, CRL-3435), MDA-MB-435 (ATCC, HTB-
129) and SKBR3 (ATCC, HTB-30) were used for this study. Both MDA-MB-435 and SKBR3 
Figure 10. The RUBYchip™ is designed to capture CTCs based on physical propertie such a size
and cellular deformability. Filtering areas are composed by interspaced micropillars, distanced from
each other in 5 µm.
The microflu dic masters were designed in 2D AutoCAD software (Autodesk Au-
toCAD 2020, Autodesk inc. CA, USA) nd f bricated in a 200 mm silicon wafer using
photolithography and de p reactive ion etching. Briefly, the silicon wafer (P/B ron, <100>,
Siegert Wafer GmbH, Aachen, Germany) was patterned using a Direct Write Laser system
(DWL 2000 Heidelberg Instruments, Heidelberg, Germany). The pattern was then etched
with sulphur hexafluoride ( , l rich/ aA, Darmstadt, Germany) by Sil-
icon De p Reactive Ion Etching (SPTS Pegasus, SPTS Technologies Ltd., Newport, England).
Trench depth was measured in betw en steps using an optical profilometer (Hyperion,
OPM profilometer, OPM Messtechnik GmbH, Ettlingen, Germany) until 20 µm depth was
reached. R sidues w re stripped using oxygen plasma, a d the master was ch racterized
by Scanning Electro Microscopy (NovaNanoSEM, FEI, Oregon, USA). Finally, the wafer
was diced (Automatic Dicing Saw, DA 3350, DISCO HI-TEC FRANCE SARL, Gardanne,
France) into the individual masters, cleaned with isopropyl alcohol (IPA, Sigma Aldrich)
and deionized water and dried at 150 ◦C on a hot plate.
Before replication, the masters were hydrophobized with a vapor-phase treatment
in trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma Aldrich) for two hours (one hour
at 65 ◦C).
After hydrophobization, for rapid prototyping using soft lithography, polydimethyl-
siloxane prepolymer was mixed with a cross-linker (PDMS, SYLGARDTM 184 Silicone
Elastomer, Dow Chemical Company, Ellsworth Adhesives, Madrid, Spain) at 10:1 ratio,
degassed, and poured over the master and cured at 65 ◦C for 2 h. Subsequently, the PDMS
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replica was unmoulded, and both inlet and outlets were punched. Finally, microscope glass
slides (size 25 × 75 mm, ThermoFisher Scientific, Darmstard, Germany) and the PDMS
replicas were treated with oxygen plasma (Plasma Cleaner PDC-002-CE, HarrickPlasma,
NY, USA) to produce irreversible bonding.
To conclude the device preparation, the chips were connected to a syringe pump
(NE-1200, New Era Syringe Pumps, Tecan France, Lyon, France) and filled with 350 µL of
ethanol (Sigma Aldrich) at 100 µL/min, 350 µL of 10 mM phosphate buffer saline (PBS,
Sigma Aldrich) at 120 µL/min, and 4000 µL of 1% Pluronic F-127 (Sigma Aldrich) at 140
µL/min for coating and preventing cell attachment onto the channel surface.
4.2. Optimization Studies
4.2.1. Cell Culture and Spiking Experiments
The human cancer cell lines MCF-7 (ATCC, CRL-3435), MDA-MB-435 (ATCC, HTB-
129) and SKBR3 (ATCC, HTB-30) were used for this study. Both MDA-MB-435 and SKBR3
cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Ther-
moFisher Scientific, Darmstard, Germany), supplemented with 10% foetal bovine serum
(FBS, Gibco) and 1% penicillin/streptomycin (Pen/Strep, Corning, NY, USA). For MCF-7
cell culture, additional 0.1% human insulin (Sigma Aldrich) supplementation was provided.
All the cell lines were cultured as a monolayer at 37 ◦C in a 5% CO2 humidified atmosphere.
To assess the isolation efficiency of the RUBYchip™, the three different cell lines were
used in spiking experiments, as follows. Two hundred cells stained with Hoechst for 30 min
were spiked in 7.5 mL of whole blood collected from healthy donors. The cells were injected
in the RUBYchip™ using a syringe pump at four different flow rates: 100, 120, 140 and 160
µL/min. Trapped cells were rinsed with 350 µL of 2% bovine serum albumin (BSA, Sigma
Aldrich) in PBS, fixed with 350 µL of 4% paraformaldehyde (PFA, Sigma Aldrich) for 20
min at room temperature (RT) and washed with PBS. The analysis of the trapped cells
was performed using a fluorescence inverted Nikon TI-E microscope. To determine the
isolation efficiency of the RUBYchip™, the number of Hoechst-positive cells trapped in the
device was compared with the total number of cells spiked, as in Equation (1). Experiments
were done in triplicate.





Immunocytochemistry (ICC) studies were performed in order to characterize the cells
trapped in the RUBYchip™. Different experimental conditions were tested to optimize
antibody staining conditions. These studies were done both in well plate and in the
microfluidic device. Negative control studies were performed in device using healthy
volunteers’ samples. Conjugated antibodies were used, meaning that direct IF studies were
performed, in order to optimize the time of preparation and incubation of the antibodies,
since protocols for direct IF are usually shorter as they only require one labelling step, and
to minimize the risk of cross contamination.
The panel of antibodies selected included monoclonal Anti-Cytokeratin pan-FITC
antibody (clone C-11, recognizes human cytokeratins 4, 5, 6, 8, 10, 13 and 18; Sigma Aldrich;
F3418; 1.9 mg/mL) to target epithelial cells; DyLight 550 Anti-ErbB2/HER2 (Immunostep®,
Salamanca, Spain; 1399990570; 0.85 mg/mL) to target cells with HER2 overexpression;
Cyanine5 Anti-Human CD45 (Immunostep®; 1399990730; 1 µg/mL) to label blood cells
(used as a CTC exclusion criteria); and DAPI (Sigma Aldrich; D9564; 1 mg/mL) to stain the
nucleus. Using a fluorescence inverted Nikon- TI-E microscope, and using NIS® Software,
it was possible to obtain multi-channel fluorescence images, with DAPI, CK, HER2 and
CD45, in the blue, green, orange and red channels, respectively.
For the ICC performed in well plate, MCF-7, MDA-MB-435, SKBR3 and PBMCs were
used. Cell lines were seeded on sterile glass coverslips (treated with Poly-Lysine) and
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allowed to grow for 24 h. PBMCs were isolated from whole blood from healthy donors
by density gradient centrifugation using Histopaque® (Sigma Aldrich). For immunoflu-
orescence staining, the cells were incubated with the antibodies described above, at the
dilutions to be tested (Table 4).
Table 4. Working dilutions tested for each of the selected antibodies in the ICCs performed.
ICC DAPI CK HER2 CD45
performed in well plate 1:5000 1:200 6 µg/mL (1:142) 1:50
performed in Device (I) 1:5000 1:300 6 µg/mL (1:142) 1:50
performed in Device (II) 1:5000 1:400 6 µg/mL (1:142) 1:100
performed in Device (III) 1:5000 1:600 6 µg/mL (1:142) 1:200
Negative Controls 1:5000 1:200 6 µg/mL (1:142) 1:50
Patient Samples 1:5000 1:200 8 µg/mL (1:106) 1:100
The same cell lines were used in the ICC performed in device; however, instead of
isolated PBMCs, whole blood from healthy donors was spiked with cell lines to mimic the
processing conditions of cancer patient samples. A total of 7.5 mL of whole blood samples
were spiked with 200 cells of each cell line, using a working cell suspension of 100 cells/100
µL, and pumped at 120 µL/min in the RUBYchip™ using a syringe pump. Whole blood
from three different healthy donors pumped at 120 µL/min in the RUBYchip™ was used
as negative control in ICC experiments.
After cell isolation and staining, images of the device were acquired using a Nikon-Ti-
E microscope, in 8 different large scans of 25 fields-of-view each, dividing the 2 rows of the
device in 4 different areas. Optimization assays were made until an ideal antibody dilution
was achieved.
In order to have an expression negative control, where no cancer cells are present,
whole blood from healthy donors was stained alone with the same selection of antibodies,
and 7.5 mL of blood was collected from three different healthy donors. The blood was
pumped at 120 µL/min in the RUBYchip™ using a syringe pump. Once sample processing
was finished, standard ICC protocol was performed as described above.
4.3. Patient Sample Collection and Processing
In the present study, 15 patients diagnosed with metastatic breast cancer were recruited
at the Hospital de Santa Maria between November 2018 and September 2019 and followed
according to the Oncology Department guidelines for disease evaluation. This study was
ethically approved by the local institutional review board at iMM and complied with all
national regulations. All patients participated voluntarily after providing written informed
consent. The study was conducted in accordance with the Declaration of Helsinki and
good clinical practice guidelines.
Clinicopathological information was recorded for all patients. As previously men-
tioned, each patient had blood collections at two time points, at a baseline and at monitoring
follow-up, after 12 weeks of ongoing treatment (Figure 11).
Fifteen millilitres of blood was collected from each patient in order to process the
samples with both technologies in parallel. CellSave® preservative tubes were used to
collect blood samples for CellSearch® analysis (Menarini-Silicon Biosystems, Bologna,
Italy), while EDTA-coated tubes were used for sample collection for the RUBYchip™.
All the samples were anonymized and encoded prior to analysis.
Processing by the RUBYchip™ was done within 4 h of collection, at the Molecular
Medicine Institute (IMM), and then fixed and shipped to the International Iberian Nan-
otechnology Laboratory (INL) within 24 h to be analysed. The samples to be processed
by CellSearch® were shipped in preservative tubes at RT to the Liquid Biopsy Analysis
Unit of the Health Research Institute of Santiago (IDIS, Spain) and processed within 96 h,
following the protocol of the manufacturer.




Figure 11. Representative chronogram of the different moments under study, namely: metastasis 
diagnosis, baseline collection and subsequent follow-up collection, for each patient. 
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Cells from patient samples isolated using the RUBYchip™ were fixed with 4% PFA 
for 20 min, permeabilized with 0.25% Triton X-100 (Sigma Aldrich) and blocked with 2% 
BSA. Isolated cells were fluorescently labelled inside the device with the antibody panel 
previously mentioned, and images were obtained using a fluorescence inverted Nikon- 
TI-E microscope. Recurring to the CK, CD45, HER2 and DAPI immunostaining as well as 
to morphological properties, such as the nucleus size, the criteria to classify cells were 
developed. After excluding debris, irregular fluorescence shapes or with a dark outline, 
the clear events with cell-like morphology were classified. 
To achieve CTC counts, cells isolated in the RUBYchip™ were manually enumerated, 
and randomized blind analysis was performed. Cells classified as DAPI+/CK+/CD45− or 
DAPI+/CK+/HER2+/CD45− were considered for CTCs enumeration. The presence of cells 
showing HER2 overexpression was also tested by confirming the presence of 
DAPI+/CK+/HER2+/CD45− cells (Table 5). The number of CTCs isolated by the RU-
BYchip™ was verified and validated by a technical expert routinely involved in the anal-







































































i t ti e r ra f
i i , li ll ti t f ll - ll ti , f r ti t.
4.4. CTC Isolation and Characterisation Using the RUBYchip
Cells from patient samples isolated using the RUBYchip were fixed with 4% PFA
for 20 min, permeabilized with 0.25% Triton X-100 (Sigma Aldrich) and blocked with 2%
BSA. Isolated cells were fluorescently labelled inside the device with the antibody panel
previously mentioned, and images were obtained using a fluorescence inverted Nikon-
TI-E microscope. Recurring to the CK, CD45, HER2 and DAPI immunostaining as well
as to morphological properties, such as the nucleus size, the criteria to classify cells were
developed. After excluding debris, irregular fluorescence shapes or with a dark outline,
the clear events with cell-like morphology were classified.
To achieve CTC counts, cells isolated in the RUBYchip™ were manually enumerated,
and randomized blind analysis was performed. Cells classified as DAPI+/CK+/CD45− or
DAPI+/CK+/HER2+/CD45− were considered for CTCs enumeration. The presence of cells
showing HER2 overexpression was also tested by confirming the presence of DAPI+/CK+/
HER2+/CD45− cells (Table 5). The number of CTCs isolated by the RUBYchip™ was verified
and validated by a technical expert routinely involved in the analysis of CellSearch® data.
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Table 5. Immunofluorescent staining characteristics for identifying CTCs.
Characteristic Cell Classification








4.5. CTC Isolation and Characterisation Using CellSearch® System
A total of 7.5 mL of blood was employed for CTCs enumeration by the CellSearch Sys-
tem, using CellSearch Epithelial Circulating Tumour Cell Kit (Menarini, Silicon Biosystems
Inc, Huntington Valley, PA, USA). This system automatically immunoisolated EpCAM+
CTCs, incubating the blood with ferrofluids coated with an anti-EpCAM antibody (clone
VU1D9). Before this incubation, 7.5 mL of blood was centrifuged at 600× g for 10 min
at RT. The system removed the plasma fraction and incubated the cell fraction with the
ferrofluids. After the isolation using a magnetic field, the system labelled the enriched
cells with phycoerythrin (PE) conjugated anti-cytokeratins (CKs, 8, 18 and 19) antibodies,
with allophycocyanin (APC) conjugated anti-CD45 antibodies, FITC-labelled anti-HER2
(CellSearch tumour phenotyping reagent HER2; (Menarini, Silicon Biosystems Inc, Hunt-
ington Valley, PA, USA) and with 4,6-diamino-2- phenylindole (DAPI) to identify the
nucleus. The CellTracks Analyzer (Menarini, Silicon Biosystems Inc, Huntington Valley, PA,
USA) was then used to acquire digital images of the four different fluorescent dyes using
a 12-bit camera. These images were reviewed by trained operators in order to determine
the CTC count. Only round/oval, intact DAPI+, CK+ and CD45− cells were considered as
CTCs. HER2 status on the CTCs was determined according to specific criteria described
by [93], scoring the HER2 intensity as negative (0), low (1), moderate (2) and high (3).
4.6. Statistical Method
Statistical analysis was performed using GraphPad Prism software, version 8 (Graph-
Pad Software, San Diego, CA, USA).
The Wilcoxon test (non-parametric inference statistical test) considering a 95% con-
fidential interval was used to compare CTC enumeration using CellSearch® versus the
RUBYchip™ technologies in the same metastatic breast cancer patient. The results were
considered statistically significant if the p-value was less than 0.05.
Kaplan–Meier curves were based on three different dichotomizations: (1) based on
the number of circulating tumour cells (cut-off as ≥5 CTC) at baseline; (2) favourable or
unfavourable patients, considering CTC count (≥5 CTC) in both time points (baseline and
follow-up collections); and (3) based on concordance of HER2 status between CTCs and
primary tumour tissue. Progression-free survival (PFS) and overall survival (OS) were
determined as the time between the baseline date and the date of next clinical progression
or death. Data were censored at last follow-up if progression or death had not occurred.
Differences in survival curves were determined using the log-rank test.
5. Conclusions
This study demonstrates the reliable, efficient and sensitive detection of CTCs in metastatic
breast cancer by using a novel microfluidic device, the RUBYchip™. The performance of the
RUBYchip™ was tested in spiked cancer cells in healthy volunteer blood samples as well as
in clinical patient samples. Concerning CTC capture and enumeration in patient samples,
the RUBYchip™ demonstrated superior performance when compared to the gold standard
technology used in the clinic, CellSearch®, in both moments of collection. The main reason
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behind this outcome is the choice of the isolation strategy regardless of the cell phenotype,
based on the size and deformability of cells, used by the RUBYchip™. In contrast, CellSearch®,
which bases cell selection on the expression of epithelial proteins in the membrane of cancer
cells, compromises the isolation of cells not expressing those specific receptors. Additionally,
the RUBYchipTM isolates CTCs in the sample with no need of any sample pre-treatment,
known to reduce the already scarce number of CTCs in the sample, which in turn contributes
to having a higher efficiency as well as increased potential of yielding feasible numbers of
viable CTCs.
The demonstrated higher capture efficiency of the RUBYchipTM proved to be funda-
mental in the accurate assessment of HER2 status in CTCs isolated from metastatic breast
cancer samples. Regarding HER2 testing, the RUBYchipTM allows to overcome limita-
tions of tissue biopsy histopathological assessment, if used concomitantly to the latter to
dynamically assess the presence of HER2+ CTCs. Furthermore, if used at subsequent moni-
toring time-points, it allows for the real-time HER2 analysis of histologically HER2-positive
MBC patients under targeted therapy. In selected patients, the RUBYchipTM detected a
shift in HER2 status from positive at baseline to negative at follow-up, in response to
anti-HER2 treatment.
Despite the fact the study presents a small cohort of 15 patients, these preliminary
findings concerning the use of RUBYchipTM in a clinical setting are indicative of tangible
added potential for clinical application in MBC. This study paves the way towards larger
multi-centre clinical trials, an imperative next step in assessing the putative clinical utility
of employing such technologies in the management of the metastatic disease and contribute
to assist in clinical decision-making.
6. Patents
The RUBYchip™ design is based on the patent PCT/EP2016/078406, filed with some
of the authors in front of the EPO on 22 November 2016, covering the geometry of the
microfluidic system for CTC isolation.
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